MADISON, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Wyeth announced today that the jury in the cases of Dana Hooper v. Wyeth and Christina Jenkins v. Wyeth in the Philadelphia Court of Common Pleas found in favor of the Company in the Hooper case. The verdict ends this case.
In the Jenkins case, the jury assessed total damages in the amount of $32,000. The second phase of this case is scheduled to begin on March 13. “We believe the defense verdict in the Hooper case was appropriate and supported by the evidence,” says Peter Grossi, an attorney from Arnold & Porter, who represented Wyeth. “In the Jenkins case, we will show in the second phase that Wyeth acted responsibly at all times and should not be held liable for any award to Ms. Jenkins.”
The trial began on February 13, 2006 before The Honorable Ricardo Jackson. The plaintiffs alleged heart valve injury from the use of the diet drug Pondimin, a drug once marketed by Wyeth. Of the six plaintiffs who were originally included in this trial group, four plaintiffs voluntarily dismissed their cases before trial. The plaintiffs were represented by the Williams Bailey and Blizzard, McCarthy & Nabers law firms of Houston, Texas.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
Wyeth
CONTACT: Media, Douglas Petkus, +1-973-660-5218, or Investor, JustinVictoria, +1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/
